CURRENT ANNOUNCEMENTS:
We are interested in the molecular mechanisms underlying individual differences in sleep, waking performance and response to sleep and wake promoting pharmacological agents in humans. To elucidate such mechanisms in health and disease, we combine and integrate methods of human genetics, selective pharmacology, multi-channel EEG, neuropsychological/cognitive testing and molecular brain imaging.
– Holst SC, Bersagliere A, Bachmann V, Berger W, Achermann P, and Landolt HP. Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans. J Neurosci 34, 566-573, 2014.
– Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Bethold T, Gomez-Mancilla B, Seifritz E, and Landolt HP. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry 73, 161-168, 2013.
– Bachmann V, Klaus F, Bodenmann S, Schäfer N, Brugger P, Huber S, Berger W, and Landolt HP. Functional ADA polymorphism increases sleep depth and reduces vigilant attention in humans. Cereb Cortex 22, 962-970, 2012.
– Rétey JV, Adam M, Khatami R, Luhmann UFO, Jung HH, Berger W, and Landolt HP. A genetic variation on the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 81, 692-698, 2007.
– Rétey JV, Adam M, Honegger E, Khatami R, Luhmann U, Jung HH, Berger W and Landolt HP (2005). A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA 102, 15676-15681.
COLLABORATIONS: